138 related articles for article (PubMed ID: 36898750)
21. Performance and Cost-Effectiveness of Computed Tomography Lung Cancer Screening Scenarios in a Population-Based Setting: A Microsimulation Modeling Analysis in Ontario, Canada.
Ten Haaf K; Tammemägi MC; Bondy SJ; van der Aalst CM; Gu S; McGregor SE; Nicholas G; de Koning HJ; Paszat LF
PLoS Med; 2017 Feb; 14(2):e1002225. PubMed ID: 28170394
[TBL] [Abstract][Full Text] [Related]
22. Biennial lung cancer screening in Canada with smoking cessation-outcomes and cost-effectiveness.
Goffin JR; Flanagan WM; Miller AB; Fitzgerald NR; Memon S; Wolfson MC; Evans WK
Lung Cancer; 2016 Nov; 101():98-103. PubMed ID: 27794416
[TBL] [Abstract][Full Text] [Related]
23. Level of knowledge on low-dose CT lung cancer screening in Sichuan province, China: a cross-sectional study.
Li R; Luo L; Tao W; Huang W; Bao T
BMJ Open; 2022 Sep; 12(9):e061987. PubMed ID: 36127104
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of screening for lung cancer with low-dose computed tomography: a systematic literature review.
Puggina A; Broumas A; Ricciardi W; Boccia S
Eur J Public Health; 2016 Feb; 26(1):168-75. PubMed ID: 26370440
[TBL] [Abstract][Full Text] [Related]
25. Systematic review of the cost-effectiveness of screening for lung cancer with low dose computed tomography.
Grover H; King W; Bhattarai N; Moloney E; Sharp L; Fuller L
Lung Cancer; 2022 Aug; 170():20-33. PubMed ID: 35700629
[TBL] [Abstract][Full Text] [Related]
26. Predicting Lung Cancer Occurrence in Never-Smoking Females in Asia: TNSF-SQ, a Prediction Model.
Chien LH; Chen CH; Chen TY; Chang GC; Tsai YH; Hsiao CF; Chen KY; Su WC; Wang WC; Huang MS; Chen YM; Chen CY; Liang SK; Chen CY; Wang CL; Lee MH; Chung RH; Tsai FY; Hu JW; Katki HA; Chatterjee N; Chanock SJ; Rothman N; Lan Q; Yang PC; Chen CJ; Chang IS; Hsiung CA
Cancer Epidemiol Biomarkers Prev; 2020 Feb; 29(2):452-459. PubMed ID: 31848206
[TBL] [Abstract][Full Text] [Related]
27. Comparing the downstream costs and healthcare utilization associated with the use of low-dose computed tomography (LDCT) in lung cancer screening in patients with and without alzheimer's disease and related dementias (ADRD).
Zhang Y; Bian J; Huo J; Yang S; Guo Y; Shao H
Curr Med Res Opin; 2021 Oct; 37(10):1731-1737. PubMed ID: 34252317
[TBL] [Abstract][Full Text] [Related]
28. Determining cost-effectiveness of lung cancer screening in urban Chinese populations using a state-transition Markov model.
Sun C; Zhang X; Guo S; Liu Y; Zhou L; Shi J; Wu N; Zhai Z; Liu G
BMJ Open; 2021 Jul; 11(7):e046742. PubMed ID: 34210726
[TBL] [Abstract][Full Text] [Related]
29. New recommendation and coverage of low-dose computed tomography for lung cancer screening: uptake has increased but is still low.
Li J; Chung S; Wei EK; Luft HS
BMC Health Serv Res; 2018 Jul; 18(1):525. PubMed ID: 29976189
[TBL] [Abstract][Full Text] [Related]
30. Lung cancer screening with low-dose computed tomography: costs, national expenditures, and cost-effectiveness.
Goulart BH; Bensink ME; Mummy DG; Ramsey SD
J Natl Compr Canc Netw; 2012 Feb; 10(2):267-75. PubMed ID: 22308519
[TBL] [Abstract][Full Text] [Related]
31. Community-based Lung Cancer Screening Results in Relation to Patient and Radiologist Characteristics: The PROSPR Consortium.
Burnett-Hartman AN; Carroll NM; Honda SA; Joyce C; Mitra N; Neslund-Dudas C; Olaiya O; Rendle KA; Schnall MD; Vachani A; Ritzwoller DP
Ann Am Thorac Soc; 2022 Mar; 19(3):433-441. PubMed ID: 34543590
[No Abstract] [Full Text] [Related]
32. Patient-Level Trajectories and Outcomes After Low-Dose CT Screening in the National Lung Screening Trial.
Iaccarino JM; Silvestri GA; Wiener RS
Chest; 2019 Nov; 156(5):965-971. PubMed ID: 31283920
[TBL] [Abstract][Full Text] [Related]
33. Cost of screening for lung cancer in Australia.
Marshall HM; Finn N; Bowman RV; Passmore LH; McCaul EM; Yang IA; Connelly L; Fong KM
Intern Med J; 2019 Nov; 49(11):1392-1399. PubMed ID: 31336016
[TBL] [Abstract][Full Text] [Related]
34. [Risk factors for lung cancer based on low-dose computed tomography screening].
Jin YJ; Tang W; Huang Y; Wang JW; Hou DH; Qi LL; Zhao SJ; Wu N
Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):222-227. PubMed ID: 32252201
[No Abstract] [Full Text] [Related]
35. Lung cancer screening with MRI: Evaluation of MRI for lung cancer screening by comparison of LDCT- and MRI-derived Lung-RADS categories in the first two screening rounds.
Meier-Schroers M; Homsi R; Gieseke J; Schild HH; Thomas D
Eur Radiol; 2019 Feb; 29(2):898-905. PubMed ID: 29992387
[TBL] [Abstract][Full Text] [Related]
36. Characteristics and Outcomes of Lung Cancer Screening Among Individuals With or Without Cancer History.
Maller B; Simmons VN; Byrne MM; Tanvetyanon T
Clin Lung Cancer; 2021 Jul; 22(4):e629-e636. PubMed ID: 33441268
[TBL] [Abstract][Full Text] [Related]
37. Performance of lung cancer screening with low-dose CT in Gejiu, Yunnan: A population-based, screening cohort study.
Wei MN; Su Z; Wang JN; Gonzalez Mendez MJ; Yu XY; Liang H; Zhou QH; Fan YG; Qiao YL
Thorac Cancer; 2020 May; 11(5):1224-1232. PubMed ID: 32196998
[TBL] [Abstract][Full Text] [Related]
38. Necessity of organized low-dose computed tomography screening for lung cancer: From epidemiologic comparisons between China and the Western nations.
Gou HF; Liu Y; Yang TX; Zhou C; Chen XZ
Oncotarget; 2017 Jan; 8(1):1788-1795. PubMed ID: 27705946
[TBL] [Abstract][Full Text] [Related]
39. Queensland Lung Cancer Screening Study: rationale, design and methods.
Marshall HM; Bowman RV; Crossin J; Lau MA; Slaughter RE; Passmore LH; McCaul EM; Courtney DA; Windsor MN; Yang IA; Smith IR; Keir BJ; Hayes TJ; Redmond SJ; Zimmerman PV; Fong KM
Intern Med J; 2013 Feb; 43(2):174-82. PubMed ID: 22471951
[TBL] [Abstract][Full Text] [Related]
40. High-risk community and primary care providers knowledge about and barriers to low-dose computed topography lung cancer screening.
Simmons VN; Gray JE; Schabath MB; Wilson LE; Quinn GP
Lung Cancer; 2017 Apr; 106():42-49. PubMed ID: 28285693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
